Why the study?
To summarize contemporary knowledge, chances, and challenges regarding the use of contact-free sensors for monitoring cardiovascular disease patients and healthy subjects.
Are contact-free sensors effective for monitoring vital signs in patients with cardiovascular disease and healthy subjects?
Are contact-free sensors effective for monitoring vital signs in patients with cardiovascular disease and healthy subjects?
Contact-free sensors show promise for non-invasive, long-term monitoring of vital signs like heart rate and respiration, though motion artifacts and lack of large cohort data remain challenges.
Contact-free sensors broaden digital biomarker monitoring options; leaves open prospective outcome validation before clinical adoption.
Multiple sensor systems are used to monitor physiological parameters, activities of daily living and behaviour. Digital biomarkers can be extracted and used as indicators for health and disease. Signal acquisition is either by object sensors, wearable sensors, or contact-free sensors including cameras, pressure sensors, non-contact capacitively coupled electrocardiogram (cECG), radar, and passive infrared motion sensors. This review summarizes contemporary knowledge of the use of contact-free sensors for patients with cardiovascular disease and healthy subjects following the PRISMA declaration. Chances and challenges are discussed. Thirty-six publications were rated to be of medium (31) or high (5) relevance. Results are best for monitoring of heart rate and heart rate variability using cardiac vibration, facial camera, or cECG; for respiration using cardiac vibration, cECG, or camera; and for sleep using ballistocardiography. Early results from radar sensors to monitor vital signs are promising. Contact-free sensors are little invasive, well accepted and suitable for long-term monitoring in particular in patient's homes. A major problem are motion artefacts. Results from long-term use in larger patient cohorts are still lacking, but the technology is about to emerge the market and we can expect to see more clinical results in the near future.
No takes yet. Share an insight, caveat, or question.
Saner et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: